These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 3625258)
81. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma. Dauer LT; St Germain J; Williamson MJ; Zanzonico P; Modak S; Cheung NK; Divgi C Health Phys; 2007 Jan; 92(1):33-9. PubMed ID: 17164597 [TBL] [Abstract][Full Text] [Related]
82. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells. Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687 [TBL] [Abstract][Full Text] [Related]
83. Intravenous lidocaine: effects on controlling pain after anti-GD2 antibody therapy in children with neuroblastoma--a report of a series. Wallace MS; Lee J; Sorkin L; Dunn JS; Yaksh T; Yu A Anesth Analg; 1997 Oct; 85(4):794-6. PubMed ID: 9322457 [No Abstract] [Full Text] [Related]
84. Cell-surface ganglioside GD2 in the immunohistochemical detection and differential diagnosis of neuroblastoma. Sariola H; Terävä H; Rapola J; Saarinen UM Am J Clin Pathol; 1991 Aug; 96(2):248-52. PubMed ID: 1713742 [TBL] [Abstract][Full Text] [Related]
85. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma. Kremens B; Hero B; Esser J; Weinel P; Filger-Brillinger J; Fleischhack G; Graf N; Grüttner HP; Niemeyer C; Schulz A; Wickmann L; Berthold F Cancer Immunol Immunother; 2002 Apr; 51(2):107-10. PubMed ID: 11904735 [TBL] [Abstract][Full Text] [Related]
86. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486 [TBL] [Abstract][Full Text] [Related]
87. Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial. Cheung IY; Mauguen A; Modak S; Ragupathi G; Basu EM; Roberts SS; Kushner BH; Cheung NK JAMA Oncol; 2023 Feb; 9(2):242-250. PubMed ID: 36547975 [TBL] [Abstract][Full Text] [Related]
90. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Uttenreuther-Fischer MM; Huang CS; Reisfeld RA; Yu AL Cancer Immunol Immunother; 1995 Jul; 41(1):29-36. PubMed ID: 7641217 [TBL] [Abstract][Full Text] [Related]
91. Impact of minimal tumor burden on antibody response to vaccination. Kim SK; Wu X; Ragupathi G; Gathuru J; Koide F; Cheung NK; Panageas K; Livingston PO Cancer Immunol Immunother; 2011 May; 60(5):621-7. PubMed ID: 21267719 [TBL] [Abstract][Full Text] [Related]
92. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Kramer K; Cheung NK; Humm JL; Dantis E; Finn R; Yeh SJ; Antunes NL; Dunkel IJ; Souwedaine M; Larson SM Med Pediatr Oncol; 2000 Dec; 35(6):716-8. PubMed ID: 11107154 [TBL] [Abstract][Full Text] [Related]
93. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Raffaghello L; Marimpietri D; Pagnan G; Pastorino F; Cosimo E; Brignole C; Ponzoni M; Montaldo PG Cancer Lett; 2003 Jul; 197(1-2):205-9. PubMed ID: 12880983 [TBL] [Abstract][Full Text] [Related]
94. Application of the murine anti-Gd-2 antibody 14.Gd-2a for diagnosis and therapy of neuroblastoma. Reuland P; Handgretinger R; Smykowsky H; Dopfer R; Klingebiel T; Miller BM; Reisfeld RA; Gallagher S; Koscelniak E; Treuner J Int J Rad Appl Instrum B; 1991; 18(1):121-5. PubMed ID: 2010296 [TBL] [Abstract][Full Text] [Related]